^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
captisol-enabled melphalan
i
Other names: CE melphalan, LGD-353
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor, Alkylating agent
Related drugs:
2ms
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial primary completion date
|
CD34 (CD34 molecule)
|
Neulasta (pegfilgrastim) • captisol-enabled melphalan
2ms
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov)
P3, N=750, Recruiting, Children's Oncology Group | Trial completion date: Sep 2026 --> Sep 2030 | Trial primary completion date: Sep 2026 --> Sep 2030
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
cisplatin • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • dexrazoxane
2ms
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov)
P3, N=750, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting
Enrollment open
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
cisplatin • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • dexrazoxane
7ms
Intra-arterial Chemotherapy for Retinoblastoma (clinicaltrials.gov)
P1, N=5, Completed, Washington University School of Medicine | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Mar 2025
Trial completion • Trial completion date
|
captisol-enabled melphalan
11ms
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation (clinicaltrials.gov)
P2, N=43, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Nov 2024
Enrollment closed • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
fludarabine IV • captisol-enabled melphalan
11ms
Intra-arterial Chemotherapy for Retinoblastoma (clinicaltrials.gov)
P1, N=5, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jan 2025 --> Jan 2026
Trial completion date
|
captisol-enabled melphalan
1year
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P2, N=43, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting
Enrollment closed
|
Campath (alemtuzumab) • fludarabine IV • captisol-enabled melphalan
1year
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
CD34 (CD34 molecule)
|
Neulasta (pegfilgrastim) • captisol-enabled melphalan
over1year
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (clinicaltrials.gov)
P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open • Pre-transplantation • Post-transplantation
|
lenalidomide • Elrexfio (elranatamab-bcmm) • busulfan • captisol-enabled melphalan • plerixafor
over1year
NCI-2018-00906: Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov)
P1/2, N=62, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
Trial completion • Trial completion date • Trial primary completion date
|
Neupogen (filgrastim) • captisol-enabled melphalan
over1year
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (clinicaltrials.gov)
P2, N=40, Completed, Case Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Jun 2024 | Active, not recruiting --> Completed
Trial completion • Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
fludarabine IV • thiotepa • captisol-enabled melphalan
over1year
NCI-2017-01069: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=35, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Feb 2024 --> May 2027 | Trial primary completion date: Feb 2024 --> Aug 2023
Trial completion date • Trial primary completion date • Post-transplantation
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
cyclophosphamide • sirolimus • fludarabine IV • captisol-enabled melphalan
Share via
